Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313636 | 1.00 | RAB9A (0.35) | RAB9A | |
| SCHEMBL9522085 | 1.00 | RAB9A (0.35) | RAB9A | |
| SCHEMBL9523655 | 1.00 | RAB9A (0.35) | RAB9A | |
| SCHEMBL1116761 | 1.00 | — | — | |
| SCHEMBL3862754 | 1.00 | RAB9A (0.35) | RAB9A | |
| SCHEMBL3208904 | 1.00 | RAB9A (0.35) | RAB9A | |
| SCHEMBL313344 | 1.00 | RAB9A (0.35) | RAB9A | |
| SCHEMBL7994720 | 1.00 | RAB9A (0.35) | RAB9A | |
| SCHEMBL291390 | 0.97 | — | — | |
| SCHEMBL291782 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037439-B2 | Water-based polymer hydrogel system | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2024-07-16 | — | — | US | disclosed |
| EP-3191484-B1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024117128-A1 | INTRAOCULAR PRESSURE LOWERING AGENT, AND AGENT FOR TREATING OR PREVENTING GLAUCOMA OR OCULAR HYPERTENSION | ＳＡＮＳＨＯ株式会社 | 2024-06-06 | — | — | WO | disclosed |
| EP-4351553-A1 | NOVEL ANTI-FIBROTIC DRUGS | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (DE) | 2024-04-17 | — | — | EP | disclosed |
| US-20240115586-A1 | THERAPEUTIC AGENT FOR PULMONARY FIBROSIS | SANSHO CO. LTD. (JP) | 2024-04-11 | — | — | US | disclosed |
| CN-117642185-A | Improved CD30 targeting antibody drug conjugates and uses thereof | 路德维希-马克西米利安慕尼黑大学 | 2024-03-01 | — | — | CN | disclosed |
| US-20240018281-A1 | WATER-BASED POLYMER HYDROGEL SYSTEM | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2024-01-18 | — | — | US | disclosed |
| US-20240018282-A1 | METHOD FOR MAKING AN AQUEOUS HYDROGEL COMPOSITION | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2024-01-18 | — | — | US | disclosed |
| US-11814459-B2 | Aqueous solution method for forming a hydrogel composition | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-11-14 | — | — | US | disclosed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| US-5962504-A | ACTIVATOR OF PROTEIN KINASE; ANTICANCER AGENT | GEORGETOWN UNIVERSITY (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999033838-A1 | 2-β-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS β-LACTAMASE INHIBITORS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1999033837-A1 | PROCESS FOR THE PREPARATION OF α-OXOLACTAMS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1999012901-A1 | SUBSTITUTED 2-PYRROLIDINONE ACTIVATORS OF PKC | GEORGETOWN UNIVERSITY (US) | 1999-03-18 | — | — | WO | disclosed |
| EP-0262399-B1 | CYCLIC ENOL DERIVATIVES, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1993-02-03 | — | — | EP | disclosed |
| EP-0259707-B1 | HYDROXYBUTENOLIDE DERIVATIVES, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1992-01-02 | — | — | EP | disclosed |
| US-4939274-A | Antiischemic agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-07-03 | — | — | US | disclosed |
| US-4925868-A | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| EP-0262399-A2 | Cyclic enol derivatives, production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1988-04-06 | — | — | EP | disclosed |
| EP-0259707-A2 | Hydroxybutenolide derivatives, production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | ABL1, PRKDC, PRKACA | RAB9A 1967/4885 |
| US-20240115586-A1 | THERAPEUTIC AGENT FOR PULMONARY FIBROSIS | CCL11, ELANE, MMP1 | RAB9A 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.